Technological advances in adoptive immunotherapy

Mathias Oelke, Christine Krueger, Jonathan P Schneck

Research output: Contribution to journalArticle

Abstract

Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases. Currently, many approaches are based on either the use of autologous peptide pulsed dendritic cells as antigen-presenting cells or nonspecific expansion of T cells. Unfortunately, current approaches lack the ability to serve as reproducible and economically viable methods. Several groups are developing new artificial approaches to overcome problems associated with dendritic cells and the nonspecific expansion of T-cell clones in order to make adoptive immunotherapy more feasible and effective. Thus, by increasing the availability of adoptive immunotherapy, we will be able to better determine the efficacy of the approaches in the treatment of a variety of diseases. In this review, we focus on technological advances that will facilitate adoptive immunotherapy. Specifically, we summarize current strategies which are either based on artificial antigen-presenting cells or on T-cell receptor gene transfer.

Original languageEnglish (US)
Pages (from-to)13-21
Number of pages9
JournalDrugs of Today
Volume41
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Adoptive Immunotherapy
T-Lymphocytes
Antigen-Presenting Cells
Dendritic Cells
CD8 Antigens
T-Cell Receptor Genes
CD4 Antigens
Cell- and Tissue-Based Therapy
Communicable Diseases
Clone Cells
Peptides
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Technological advances in adoptive immunotherapy. / Oelke, Mathias; Krueger, Christine; Schneck, Jonathan P.

In: Drugs of Today, Vol. 41, No. 1, 01.2005, p. 13-21.

Research output: Contribution to journalArticle

Oelke, Mathias ; Krueger, Christine ; Schneck, Jonathan P. / Technological advances in adoptive immunotherapy. In: Drugs of Today. 2005 ; Vol. 41, No. 1. pp. 13-21.
@article{5cb2630dbabc431788ee91c272f24460,
title = "Technological advances in adoptive immunotherapy",
abstract = "Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases. Currently, many approaches are based on either the use of autologous peptide pulsed dendritic cells as antigen-presenting cells or nonspecific expansion of T cells. Unfortunately, current approaches lack the ability to serve as reproducible and economically viable methods. Several groups are developing new artificial approaches to overcome problems associated with dendritic cells and the nonspecific expansion of T-cell clones in order to make adoptive immunotherapy more feasible and effective. Thus, by increasing the availability of adoptive immunotherapy, we will be able to better determine the efficacy of the approaches in the treatment of a variety of diseases. In this review, we focus on technological advances that will facilitate adoptive immunotherapy. Specifically, we summarize current strategies which are either based on artificial antigen-presenting cells or on T-cell receptor gene transfer.",
author = "Mathias Oelke and Christine Krueger and Schneck, {Jonathan P}",
year = "2005",
month = "1",
doi = "10.1358/dot.2005.41.1.875775",
language = "English (US)",
volume = "41",
pages = "13--21",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Technological advances in adoptive immunotherapy

AU - Oelke, Mathias

AU - Krueger, Christine

AU - Schneck, Jonathan P

PY - 2005/1

Y1 - 2005/1

N2 - Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases. Currently, many approaches are based on either the use of autologous peptide pulsed dendritic cells as antigen-presenting cells or nonspecific expansion of T cells. Unfortunately, current approaches lack the ability to serve as reproducible and economically viable methods. Several groups are developing new artificial approaches to overcome problems associated with dendritic cells and the nonspecific expansion of T-cell clones in order to make adoptive immunotherapy more feasible and effective. Thus, by increasing the availability of adoptive immunotherapy, we will be able to better determine the efficacy of the approaches in the treatment of a variety of diseases. In this review, we focus on technological advances that will facilitate adoptive immunotherapy. Specifically, we summarize current strategies which are either based on artificial antigen-presenting cells or on T-cell receptor gene transfer.

AB - Adoptive immunotherapy is an attractive and elegant strategy for treating a variety of life-threatening diseases. Several approaches have been developed to generate antigen-specific CD4+ and CD8+ T cells for adoptive T-cell therapy in cancer and infectious diseases. Currently, many approaches are based on either the use of autologous peptide pulsed dendritic cells as antigen-presenting cells or nonspecific expansion of T cells. Unfortunately, current approaches lack the ability to serve as reproducible and economically viable methods. Several groups are developing new artificial approaches to overcome problems associated with dendritic cells and the nonspecific expansion of T-cell clones in order to make adoptive immunotherapy more feasible and effective. Thus, by increasing the availability of adoptive immunotherapy, we will be able to better determine the efficacy of the approaches in the treatment of a variety of diseases. In this review, we focus on technological advances that will facilitate adoptive immunotherapy. Specifically, we summarize current strategies which are either based on artificial antigen-presenting cells or on T-cell receptor gene transfer.

UR - http://www.scopus.com/inward/record.url?scp=15344346243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15344346243&partnerID=8YFLogxK

U2 - 10.1358/dot.2005.41.1.875775

DO - 10.1358/dot.2005.41.1.875775

M3 - Article

C2 - 15753966

AN - SCOPUS:15344346243

VL - 41

SP - 13

EP - 21

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 1

ER -